Nov 17, 2022 / 09:10PM GMT
Suji Jeong - Jefferies - Analyst
Good morning, everyone. My name is Suji Jeong. I'm one of the Jefferies biotech research analysts here. This morning, it's my great pleasure to introduce Inozyme Pharma, a company developing enzyme replacement therapy for life-threatening orphan disease.
And joining us here is Axel Bolte, the CEO of Inozyme.
So, Axel, take [it] away.
Axel Bolte - Inozyme Pharma, Inc. - President, CEO, Director
Thank you very much, Suji. And good morning, everybody. Delighted to be here. Thank you to Jefferies for the opportunity to talk about Inozyme.
So, five years ago, we started on our mission to fulfill an unmet medical need with therapeutic breakthroughs in rare diseases of pathologic mineralization and intimal proliferation. And it was a promising scientific opportunity at that time, and today is a potential first-in-class therapy, and a new treatment paradigm for an untapped commercial opportunity.
On this slide, I'm pointing you to our forward-looking statements. So, Inozyme is focused on rare and
Inozyme Pharma Inc at Jefferies London Healthcare Conference Transcript
Nov 18, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers